Evuzamitide Detects Cardiac Amyloidosis Across Subtypes

Company: Bayer (via Attralus) · Tracer: Iodine-124 Evuzamitide (AT-01) · Trial: REVEAL (Phase III) · Indication: Cardiac Amyloidosis Diagnosis · Date: August 30, 2026 Summary The prospective Phase 3 REVEAL study found that iodine-124 evuzamitide PET/CT detected cardiac amyloidosis with 94% sensitivity and 86% specificity…